港股异动 | 和誉-B(02256)涨超7% 附属和誉医药与默克就Pimicotinib（ABSK021）达成独家许可协议
和誉-B(02256)涨超7%，截至发稿，涨7.11%，报4.52港元，成交额839.5万港元。
消息面上，公司附属和誉医药宣布已与默克公司就其自主研发的CSF-1R小分子抑制剂Pimicotinib（ABSK021）达成独家许可协议。根据协议条款，默克将获得在中国内地、中国台湾、中国香港和中国澳门针对Pimicotinib就所有适应症进行商业化的许可，和誉医药将保留在授权区域内独家开发Pimicotinib的权利。
此外，和誉医药亦已向默克授予Pimicotinib全球商业化权利的独家选择权(全球商业化选择权)。根据协议条款，和誉医药将获得7000万美元的一次性、不可退还的首付款，如果默克行使全球商业化选择权，和誉还将获得额外的行权费；加上研发里程碑付款及销售里程碑付款，以上潜在的付款总额可能高达6.055亿美元，除此之外默克还将向和誉医药支付两位数百分比的销售提成。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.